Plus Therapeutics subsidiary to present data on CNSide CSF Assay Platform

CNSide Diagnostics, a wholly owned subsidiary of Plus Therapeutics (PSTV), will present data demonstrating the utility of the CNSide CSF Assay Platform in identifying mutations of key biomarkers in the CSF and their implications in treatment selection for LM. The data will be presented at the 2024 Society for NeuroOncology, SNO, Annual Meeting November 21-24 in Houston, Texas. “The data from CNSide suggests that biomarker mutation profiles in LM are dynamic, offering valuable insights for treatment strategies,” said Marc H. Hedrick, M.D., Plus Therapeutics’ President and Chief Executive Officer. “The genetic drift observed in LM suggests an important role for radiotherapeutics such as Rhenium Obisbemeda in addressing this challenging disease.”